Recursion Pharmaceuticals director Blake Borgeson sells $97,500 in stock By Investing.com

Blake Borgeson, a director at Recursion Pharmaceuticals (), sold 30,000 shares of the company’s Class A Common Stock on August 4, 2026, for a total value of $97,500.

The shares were sold at a price of $3.25 per share. This transaction was executed under a Rule 10b5-1 trading plan, which Mr. Borgeson adopted on August 31, 2025. Following this sale, Mr. Borgeson directly holds 6,188,287 shares of Recursion Pharmaceuticals Class A Common Stock.The insider transaction comes as the stock has declined 41% over the past year, currently trading at $3.18. According to InvestingPro analysis, the company appears undervalued at current levels, with shares trading below Fair Value. However, one of eight InvestingPro Tips highlights that the company is quickly burning through cash, which may be relevant context for insider activity. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for RXRX and 1,400+ other US equities.

In other recent news, Recursion Pharmaceuticals reported its financial results for the second quarter of 2026, revealing a significant revenue shortfall. The company posted revenue of $7.67 million, falling short of the $12.15 million forecast by analysts. Additionally, Recursion reported an adjusted loss of $0.25 per share, slightly larger than the anticipated $0.24 per share loss. In response to these financial results, the company announced a reduction in its full-year cash operating expense guidance to $375 million. Recursion also noted that its current cash balance of approximately $557 million is expected to support operations through early 2028. These recent developments have drawn attention from investors and analysts alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.